Compare SPDR Gold Trust (GLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Spyre Therapeutics Inc. Common Stock — how do they compare? SPDR Gold Trust trades at $380.65 (market cap $141.50B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: SPDR Gold Trust is far larger — about 19.3× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GLD | SYRE | |
|---|---|---|
Market Cap | $141.50B | $7.35B |
Volume | 5,707,251 | 1,624,631 |
52-Week High | $495.90 | $108.92 |
52-Week Low | $362.32 | $22.18 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, trades at $381.67, down 0.13% amid pressure from rising Treasury yields and a stronger U.S. dollar. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with prices testing key support levels near $380.
The outlook for GLD hinges on interest rate trends and macroeconomic uncertainty. While gold serves as a hedge against inflation and debt concerns, near-term headwinds from elevated yields and Fed policy uncertainty pose risks. A tactical buying opportunity may emerge if support holds, but sustained gains require a shift in monetary policy sentiment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
